Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

BACKGROUND: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ely, E Wesley, Ramanan, Athimalaipet V, Kartman, Cynthia E, de Bono, Stephanie, Liao, Ran, Piruzeli, Maria Lucia B, Goldman, Jason D, Saraiva, José Francisco Kerr, Chakladar, Sujatro, Marconi, Vincent C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813065/
https://www.ncbi.nlm.nih.gov/pubmed/35123660
http://dx.doi.org/10.1016/S2213-2600(22)00006-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813065/
https://www.ncbi.nlm.nih.gov/pubmed/35123660
http://dx.doi.org/10.1016/S2213-2600(22)00006-6

Ejemplares similares